Quick Answer
Kyverna Therapeutics, Inc. reported Total Assets of $293.83 million for fiscal year 2025.
Kyverna Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $293.83M | -3.6% |
| 2024 | $304.64M | +305.1% |
| 2023 | $75.19M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $187.16M | -44.8% | -17.4% |
| June 30, 2025 | $226.51M | -37.6% | -13.1% |
| March 31, 2025 | $260.65M | -33.2% | -14.4% |
| December 31, 2024 | $304.64M | +305.1% | -10.2% |
| September 30, 2024 | $339.20M | — | -6.6% |
| June 30, 2024 | $363.12M | — | -6.9% |
| March 31, 2024 | $389.98M | — | +418.6% |
| December 31, 2023 | $75.19M | — | — |
- Kyverna Therapeutics, Inc. showed a decrease of -3.6% in Total Assets compared to the prior fiscal year.
- Over the 2023–2025 period, Kyverna Therapeutics, Inc.’s total assets has grown by 290.8% (from $75.19 million to $293.83 million).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: